8-K current report · filed Nov 10, 2026

Stereotaxis, Inc. (STXS) 8-K Current Report: November 10, 2026

Item 1.01Item 2.02Item 2.03Item 3.02Item EX-99.1Item EX-99.2STXS overview

Short answer

Stereotaxis, Inc. (STXS) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $12.0M initial convertible note financing closed, with potential additional proceeds up to $12.0M.

Stereotaxis, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $12.0M initial convertible note financing closed, with potential additional proceeds up to $12.0M
  • Notes carry 10% annual interest, mature November 9, 2029, and generally defer interest through payment-in-kind accrual
  • $1.21 conversion price for Initial Notes, set at a 30% premium to the prior 10-day VWAP
  • Financing introduces dilution risk, capped at 20,070,290 shares, or 19.9% of pre-financing shares
  • Proceeds fund working capital, commercialization acceleration, research and development, and general corporate needs

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced by Stereotaxis on November 10, 2026
  • Full results and management commentary available in Exhibit 99.1, the earnings press release

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 confirms new indebtedness through the Notes referenced under Item 1.01
  • Debt terms, principal amount, interest rate, maturity and use of proceeds require review of Item 1.01
  • Notes create direct financial obligations that may increase leverage and future cash-interest requirements

Item 3.02 · Unregistered Sales of Equity Securities

  • Private issuance of Notes and related shares under the Note Financing, outside a public offering
  • Financing completion and additional draws remain subject to required regulatory approvals
  • Potential equity dilution from shares issued with the Notes
  • Proceeds intended to support Stereotaxis and acquired Robocath operations, subject to execution risks

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $8.9M, up 20% year over year and 16% sequentially, led by system revenue growth to $3.0M
  • Recurring revenue $5.9M, up 6% year over year but down 4% sequentially amid catheter supply constraints
  • Gross margin 45%, with recurring revenue margin 59% versus system margin 15%, highlighting profitability dependence on recurring sales
  • Adjusted operating loss $5.1M and negative cash flow $6.5M, including $3.9M of Robocath acquisition payments
  • Liquidity pressure: cash $4.0M at September 30, supplemented by $12M convertible-note proceeds and potential additional $12M draw

Item EX-99.2 · Exhibit EX-99.2

  • Up to $24 million convertible financing: $12 million upfront plus $12 million available after regulatory milestones
  • 10% annual interest, accrued until maturity in three years, increasing future cash obligations
  • Conversion price $1.21 per share, a 30% premium to the prior 10-day VWAP, limiting immediate dilution unless converted
  • Pro forma cash $16 million, with total potential availability of $28 million including the optional draw
  • Proceeds support working capital, commercialization acceleration, research and development, and general corporate needs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Stereotaxis, Inc. 8-K filings

Get the next STXS 8-K as it lands

Follow STXS for push alerts, or ask the research agent what this filing means.